Blog
RSS FeedPosted by Michael Wonder on 03 Jun 2021
A consultancy firm was paid $660,000 to advise on Australia's COVID-19 vaccine strategy. But a government official said they provided no 'specific advice'.
3 June 2021 - McKinsey was paid $660,000 by the Health Department as part of the federal government's COVID-19 vaccine ...
Posted by Michael Wonder on 03 Jun 2021
'We're not just all about the money' — PHARMAC defends why it still won't fund drug for rare children's disorder
3 June 2021 - Under-fire PHARMAC is defending the way it funds New Zealand's drugs, with the agency's director of operations, ...
Posted by Michael Wonder on 03 Jun 2021
Quebec extends public reimbursement of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis to include adolescents
1 June 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec will now apply for Canadians aged ...
Posted by Michael Wonder on 02 Jun 2021
NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group
2 June 2021 - NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in ...
Posted by Michael Wonder on 02 Jun 2021
NICE draft guidance does not recommend risdiplam for treating spinal muscular atrophy
2 June 2021 - NICE has today published draft guidance for public consultation which does not recommend risdiplam (Evrysdi, Roche) for ...
Posted by Michael Wonder on 02 Jun 2021
PHARMAC works well. Unless you’re sick.
2 June 2021 - Nearly two decades ago, in Washington DC, a group of consultants, lobbyists, lawyers and pharmaceutical industry ...
Posted by Michael Wonder on 01 Jun 2021
PHARMAC petition tabled at Parliament
1 June 2021 - A petition with more than 100,000 signatures has today been tabled at Parliament after being accepted ...
Posted by Michael Wonder on 31 May 2021
New EU health innovation rules edge closer
29 May 2021 - Three years after the original proposal, the European Union’s game changing Health Technology Assessment dossier has ...
Posted by Michael Wonder on 31 May 2021
Roche Canada announces collaboration to improve access to personalised health care with real world evidence
28 May 2021 - BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate ...
Posted by Michael Wonder on 31 May 2021
Schedule of Pharmaceutical Benefits - 1 June 2021
1 June 2021 - The June 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 May 2021
Campaign launched for life-sustaining treatment access across Canada
31 May 2021 - Alpha-1 Canada publicly launched Access for Alphas today, a campaign aimed at raising the awareness of alfa-1 ...
Posted by Michael Wonder on 31 May 2021
New Zealand Pharmaceutical Schedule - 1 June 2021 update
1 June 2021 - The June 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 May 2021
Examining the impact of different country processes for appraising rare disease treatments: a case study analysis
31 May 2021 - Conventional appraisal and reimbursement processes are being challenged by the increasing number of rare disease treatments with ...
Posted by Michael Wonder on 31 May 2021
Apotex medicines in New Zealand
31 May 2021 - Apotex has announced that it is leaving the New Zealand market. ...
Posted by Michael Wonder on 30 May 2021
PHARMAC funding will result in health poverty: advocate
30 May 2021 - A Dunedin patient rights campaigner is vowing to fight on in the wake of the Government’s ...